What You Should Know:
– Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Biotres Cardiac Monitoring Device, a three-lead device for ECG and arrhythmia monitoring that is intended for lower-risk patients.
– Most remote cardiac monitors are passive — they don’t record ECG and other cardiac data in real-time — and lack cross-compatibility with other platforms/devices. Conversely, Biotricity’s expanding suite of cardiac monitoring technologies is a turn-key solution offering the kind of advanced, continuous monitoring that allows cardiologists to see warning signs earlier and act proactively, and integrates seamlessly into existing systems. The Biotres not only expands our product portfolio, it opens up a new market and increases Biotricity’s Total Addressable Market from $1B to $5.7 Billion and will be widely available for sale starting April 1, 2022
– The Biotres not only expands our product portfolio, it opens up a new market and increases Biotricity’s Total Addressable Market from $1B to $5.7 Billion and will be widely available for sale starting April 1, 2022.
